Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine)

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

• Background
  • Potential Benefits of Companion Diagnostics
  • Pitfalls of Personalized Medicine
  • Scope and Methodology
  • Market Factors and Estimates
  • Drivers For Companion Diagnostics
  • Assumptions
  • Important Trends
  • Possible Tactic: Royalty Model

CHAPTER TWO: OVERVIEW OF COMPANION DIAGNOSTICS

• Personalized Medicine
• Potential Benefits
• Privacy and Public Perception
• Biomarkers and Companion Diagnostics
  • Types of Biomarkers

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

• Pharmacogenetics and Pharmacogenomics
• Historical Basis
• Current Techniques
• Requirements
• Cost-effectiveness
• Applications
  • The Cytochrome System
  • Cancer
  • Amgen
  • UAMS Multiple Myeloma Project
  • DakoAssay for TOP2A
  • GE and Eli Lilly
  • Epigenomics and Abbott
  • Celera and Merk
  • bioMerieiux and Ipsen
  • Acute Lymphoblastic Leukemia
• Regulatory Agencies
• Applications of Genome More Challenging Than Expected
• Cardiovascular Disease
• RAS polymorphisms With Drug Effectiveness
  • Pgp
  • Thiazide diuretics
  • 825T allele
  • HIT
  • Statins
• Psychiatry and Pharmacogenetics/Pharmacogenomics
• Is Herceptin a Paradigm?
• A Balancing Act Between the Players

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

• Estimating Market Potential
• Associated Testing
• The Needs of Pharma and of Diagnostic Companies
• Questions Determining Companion Diagnostics Growth
• A Partial Change in Attitude
• Intellectual Property
• Cancer Market Potential Estimate
• Ideal Market Potential - Cancer, Heart Disease, Psychiatric
• Source: Kalorama Information
• Challenges Unique to Companion Diagnostics
• Privacy Concerns
• Fear of Learning About Diseases
• Use of Remnant Samples
• Avoiding Pitfalls of Market Calculation
• Companion Diagnostics Not Linked to Molecular Diagnostics
• Demonic and SNP Analysis
• Considering Time of Cooperative Development
• Market Realities to Consider
• Possible Tactic: Royalty Model

CHAPTER FIVE: COMPANY SUMMARIES

• Overview
• Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
• Affymetrix, Inc.
• Agilent Technologies, Inc
• Althea Technologies, Inc.
• Curidium Medica plc
• Dako
• Gen Probe
• Genzyme Corporation
• Ipsogen SAS
• Lipomics Technologies, Inc.
• Osmetech plc
• Perlegen Sciences
• Provista Life Sciences
• Qiagen NV
• Singulex, Inc.
• Theranostics Health
• Ventana Medical Systems

CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications: Seventh Conclusion Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:

APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
• Figure 1-1: Market Projection Trends for Companion Diagnostics in the United States: 2008 - 2018

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

• Table 3-1: Companion Diagnostics Groups
• Table 3-3: Frequency of Recessive Traits
• Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
• Table 3-5: Recent Activities in Companion Diagnostics

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

• Table 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
• Figure 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
• Table 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
• Figure 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
• Figure 4-3: The Ideal Companion Diagnostics Market (Ideal vs. Likely to Benefit)
• Figure 4-4: Subset of Ideal Market Likely to Benefit From Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market)
• Table 4-3: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
• Figure 4-1: Market Projection Trends for Companion Diagnostics* in the United States: 2008 - 2018

CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS

• Table 6-1: Hypothetical Cancer Therapy Outcome Based on Associated Genes